ReviewInternational journal of molecular sciences2019
Platinum Salts in Patients with Breast Cancer: A Focus on Predictive Factors.
Review in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 65 citations in OpenAlex.
- Outcomes of patients with HER2-negative metastatic breast cancer after platinum- and non-platinum-based first-line chemotherapy among patients with and without pathogenic germline BRCA1/2 mutations.British journal of cancer · 2022Trial
- Heritability of Low ER Staining/HER2-Breast Tumors: Are We Missing an Opportunity for Germline Testing?Genes · 2020Trial
- Severe anemia as a risk factor in Japanese patients with ovarian cancer receiving olaparib: a retrospective study.BMC cancer · 2026Article
- Effect of HER2-low expression on the efficacy of neoadjuvant chemotherapy in triple-negative breast cancer.Scientific reports · 2025Article
- DNA repair and the contribution to chemotherapy resistance.Genome medicine · 2025Review
- Genomic landscape and homologous recombination repair deficiency signature in stage I-III and de novo stage IV primary breast cancers.The oncologist · 2025Article
- Article
- Recent innovations in nanomedicine and nano-based techniques for the treatment of breast cancer.BioImpacts : BI · 2025Review
- A Comprehensive Review on the State of the Art of Breast Cancers in Italy.Current medicinal chemistry · 2024Review
- Early-stage triple negative breast cancer: the therapeutic role of immunotherapy and the prognostic value of pathological complete response.Exploration of targeted anti-tumor therapy · 2024Review
- Naples score: a novel prognostic biomarker for breast cancer patients undergoing neoadjuvant chemotherapy.Journal of cancer research and clinical oncology · 2023Article
- Review
- Suppressing Src-Mediated EGFR Signaling by Sustained Calcium Supply Targeting Triple-Negative Breast Cancer.International journal of molecular sciences · 2023Article
- Revisiting Two Decades of Research Focused on Targeting APE1 for Cancer Therapy: The Pros and Cons.Cells · 2023Review
- Platinum-Nucleos(t)ide Compounds as Possible Antimetabolites for Antitumor/Antiviral Therapy: Properties and Perspectives.Pharmaceutics · 2023Review
- Current Treatment Landscape for Early Triple-Negative Breast Cancer (TNBC).Journal of clinical medicine · 2023Review
- Facing the conundrum: which first-line therapy should be used for patients with metastatic triple-negative breast cancer carrying germlineExploration of targeted anti-tumor therapy · 2023Review
- Prognostic stratification of endometrial cancers with high microsatellite instability or no specific molecular profile.Frontiers in oncology · 2023Article
- The potential role of nanomedicine in the treatment of breast cancer to overcome the obstacles of current therapies.Frontiers in pharmacology · 2023Review
- Anti-Androgenic Therapies Targeting the Luminal Androgen Receptor of a Typical Triple-Negative Breast Cancer.Cancers · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Breast cancer (BC) is the most frequent oncologic cause of death among women and the improvement of its treatments is compelling. Platinum salts (e.g., carboplatin, cisplatin, and oxaliplatin) are old drugs still used to treat BC, especially the triple-negative subgroup. However, only a subset of patients see a concrete benefit from these drugs, raising the question of how to select them properly. Therefore, predictive biomarkers for platinum salts in BC still represent an unmet clinical need. Here, we review clinical and preclinical works in order to summarize the current evidence about predictive or putative platinum salt biomarkers in BC. The association between
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.